Shockwave Medical
Shockwave Medical makes intravascular lithotripsy medical devices that help physicians treat calcified cardiovascular disease.
- Acquired, subsidiary of Johnson & Johnson
- Santa Clara, CA, USUnited States
Shockwave Medical makes intravascular lithotripsy medical devices that help physicians treat calcified cardiovascular disease.
shockwavemedical.comCrawled Oct 22, 2026
Shockwave Intravascular Lithotripsy (IVL) simplifies the treatment of calcium via a unique mechanism of action (MOA) on an intuitive platform that's predictably safe and consistently effective.
Shockwave IVL treats calcified peripheral artery disease in office-based labs.
The page offers instructions and technical sheets for Shockwave intravascular lithotripsy (IVL) devices.
Shockwave Medical’s portfolio includes cardiovascular disease solutions for the heart and both above and below the knee.
The page describes a case involving 24 Fr TEVAR delivery through calcified iliacs.
Investigators present the 30-day primary endpoint analysis of the Disrupt CAD III study, the largest and most rigorous coronary IVL study to date.
The Calcium Masterclass covers clinical evidence and algorithms.
During a late-breaking clinical trial session at VIVA22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III OS.
Shockwave Medical will showcase devices and educational sessions at EuroPCR 2025.
Check here for the latest Shockwave press releases, newsletters and other key updates.
Shockwave Medical will attend TCT in San Francisco to celebrate one million patients treated with Shockwave IVL.
The page provides details on Shockwave coronary IVL reimbursement payments.
Going further into Shockwave peripheral Intravascular Lithotripsy (IVL) reimbursement payments.
Shockwave Medical aims to secure high-level reimbursement for Shockwave intravascular lithotripsy (IVL).
The team at Shockwave Medical works to transform treatment for patients with complex cardiovascular challenges.
Colin serves as Shockwave's Commercial Operations leader overseeing Sales Operations, Field Inventory, Customer Service, Contract Administration, Market Analytics and Modeling.
From IVL to coronary sinus reduction, Shockwave Medical is transforming standards of care and driving better outcomes for underserved patients.
General Shockwave Medical terms and conditions for Canada.
Shockwave Medical Terms and Conditions
These Website Terms of Use are a binding contract between the individual using the Shockwave Medical website and Shockwave Medical Inc.
Johnson & Johnson introduces the **Shockwave C2 Aero Fly Coronary IVL Catheter**, a new device designed to treat calcified coronary artery lesions. The catheter reduces treatment time by half compared to prior coronary IVL (intravascular lithotripsy) devices. It builds on the Shockwave IVL platform, delivering pulses at double the speed while maintaining its distinct mechanism of action.
Oct 2026JNJ.comNews article
Johnson & Johnson MedTech rebrands Shockwave Medical to integrate its vascular intervention technologies. The move consolidates Shockwave’s expertise in treating peripheral artery disease under the J&J MedTech umbrella. The company’s Shockwave C2 and other devices will now operate under the Johnson & Johnson brand.
Sep 2026Endovascular TodayNews article
Johnson & Johnson launches the **Shockwave C2 Aero Coronary IVL Catheter**, a next-generation device for treating calcified coronary artery disease. The catheter improves deliverability, lesion crossing, and repositioning capabilities, building on the legacy of its Shockwave IVL platform. The product targets enhanced procedural efficiency in coronary interventions.
May 2026Shockwave MedicalNews article
Shockwave Medical introduces the **Javelin Peripheral Intravascular Lithotripsy Catheter** in the U.S., a device designed to modify and cross severely calcified or occluded lesions in peripheral arteries. The platform targets difficult-to-treat cases of peripheral artery disease (PAD) by enabling safer intervention in narrowed or blocked vessels. Early availability marks a step toward expanding treatment options for patients with complex vascular conditions.
Mar 2025PR NewswireNews article